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 The IIH patients with pre-existing psychiatric diagnosis had more often empty 
sella at diagnosis  







Objective: Idiopathic intracranial hypertension (IIH) is aetiologically unknown disorder that 
associates with endocrinological disturbances, including dysfunction of hypothalamic-
pituitary-adrenal-axis. Neuroendocrinological dysfunctions have also been characterized in 
psychiatric disorders, and therefore we investigated the presence of psychiatric disorders of 
patients with IIH in a well-defined cohort. 
Patients and Methods: A total of 51 patients with IIH were included. Patient 
demographics, symptoms, imaging data, ophthalmological and clinical findings were 
collected. 
Results: At the time of diagnosis the mean age was 32.5years (SD 10.7), the body mass 
index was 37.1kg/m2 (SD 7.4), and the opening pressure 29.1mmHg (SD 6.2). A total of 
88.2% of patients were female and 45.1% were diagnosed with a psychiatric co-morbidity 
prior to IIH diagnosis. The mean follow-up time was 4.4 years (SD 5.4). The overall treatment 
outcome was significantly poorer on a group of patients with psychiatric diagnosis when 
compared to individuals without such history (p=0.001), but there were no differences in the 
resolution of papilledema (p=0.405). Patients with IIH and psychiatric disorders had more 
often empty sella on their imaging at diagnosis when compared to patients without 
psychiatric co-morbidity (p=0.044). 
Conclusion: Psychiatric disorders are highly prevalent in patients with IIH and associate 
with worse subjective outcomes. These findings advocate for monitoring the mental health of 
patients with IIH and warrant further multidisciplinary research to understand the potentially 
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1. Introduction  
 
Idiopathic intracranial hypertension (IIH) is rare disease with an incidence rate of 0.5-
2.0/100,000/year1,2. IIH predominantly affects obese women of fertile age1, whereas in the 
paediatric population the gender distribution is equal1,3. The patients with IIH are 
characterised by chronic headaches, pulsatile tinnitus, diplopia, visual disturbances, bilateral 
papilledema, and increased intracranial pressure without hydrocephalus or intracranial 
mass1,3. Classical neuroradiological findings include empty sella turcica, flattening of the 
posterior sclerae, tortuosity and distension of the subarachnoid perioptic spaces, and 
protrusion of the optic nerves4,5. 
 
The constantly elevated intracranial pressure threatens the visual system as ischemia from 
poor perfusion of the optic nerve can result in atrophy, causing permanent visual loss. 
Therefore, it is paramount to recognise this rare condition early and treat it urgently, as up to 
24% suffer from permanent visual loss and 4% report bilateral blindness at the final follow-
up1,6-8. The primary treatment goal for IIH is lowering the ICP with weight loss1,9 and 
acetazolamide medication1,10. Acetazolamide is carbonic anhydrase inhibitor limits formation 
of bicarbonate and hydrogen ions, which may be the mechanism for lowering intracranial and 
intraocular pressure11. If these conservative treatments are insufficient in resolving the 
condition, surgical intervention is required. Neurosurgical intervention includes optic nerve 
sheath fenestration, shunting procedures1,3 as well as venous sinus stenting12. In severely 
obese patients, gastric bypass surgery may also be an effective treatment of the IIH13,14. 
 
IIH patients frequently display chronic fatigue, depression, anxiety, cognitive decline and 
lowered quality of life20-26. The comorbidity between symptoms of affective disorders and IIH 
could result from common biological pathways related to hypothalamus-pituitary-adrenal 
cortex (HPA)-axis dysfunction16,27. IIH populations are also characterized by metabolic co-
morbidities 1,3,19 which may contribute to neuroendocrinological homeostasis. Although a few 
case studies have reported depression in association with IIH several decades ago28, studies 
have so far not attempted to evaluate the role of psychiatric disorders during the natural 
course of the disease. In the present study, we characterised the presence of psychiatric 
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2. Material and methods 
 
2.1. Study cohort 
This was a retrospective study on patients with International Statistical Classification of 
Diseases and Related Health Problems (ICD-10) G93.2 diagnosis, collected between 
January 1, 2000 and December 31, 2018, and formed a part of ‘’Phenotype, Pathophysiology 
and Prognostic Factors of IIH’’ study. Clinical data of treatment periods and follow-up visits 
from referring hospitals and Kuopio University Hospital (KUH) have been included into the 
Kuopio IIH database. Relevant medical charts, operative reports, laboratory results, imaging 
findings, and clinical follow-up evaluations were analysed up until April 30th, 2019. Friedman 
criteria were applied to determine eligibility for inclusion in the database29. After the exclusion 
of i) ten paediatric patients, under the age of 16 years, ii) two secondary IIH cases caused by 
venous sinus thrombosis, and iii) two suspected IIH cases that were not true IIH cases in a 
retrospective review according to the Friedman criteria, we included 51 adult patients with IIH 
(Figure 1).   
 
2.2. Clinical and Treatment variables 
The following variables were used in the analyses for patients with IIH: 
 
Before diagnosis of IIH 
1. history of psychiatric diseases (diagnoses based on the International Classification of 
Diseases (ICD-10) and the use of any psychopharmaceutical medication); 
2. other medical history (diagnosed co-morbidities);  
 
Baseline at diagnosis of IIH 
3. patient demographics (sex, age, body mass index (BMI) presenting symptoms and CSF 
opening pressure (OP)); 
4. neuro-ophthalmological findings (visual acuity, papillae and visual fields); 
5. magnetic resonance imaging (MRI) data evaluated by a neuroradiologist;  
 
Follow up during treatment of IIH  
6. treatment types, either conservative (weight loss, medication), surgical treatments (CSF 
diversion, gastric by-pass), or combined;  
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8. neuro-ophthalmological outcome (degree of papilledema) was classified as a) no 
papilledema, b) partial resolution of papilledema, and c) no improvement;  
9. symptomatic outcome was characterised as follows a) symptomless, b) partial recovery, 
i.e. on-going symptoms such as headache, tinnitus, fatigue, dizziness, balance problems 
and need for continuing medical treatment, c) no improvement.  
 
2.3. Statistical analysis  
The continuous variables were reported as means with standard deviations (SD), and the 
categorical variables were reported by using frequencies and percentages. The continuous 
variables were analysed with Student’s t-test or Fisher’s exact test. The categorical variables 
were evaluated using Pearson’s χ2 analysis. In all statistical analyses a p-value of < 0.05 
was considered statistically significant. SPSS 22.0 (SPSS, Inc, Chicago, IL) was used. 
 
2.4. Ethical aspects 
The study has been approved by the Ethics Committee of the Kuopio University Hospital 
(284/2016). Informed consent was obtained from all patients. ‘The Strengthening the 
Reporting of Observational Studies in Epidemiology’ (STROBE) guidelines were used in 




3.1. Patient and clinical characteristics of IIH at diagnosis 
A total of 51 patients were included in the study, with a mean follow-up time of 4.4 (SD 5.4) 
years.  Majority of patients were females (88.2%), with a mean age of 32.5 (SD 10.7) years 
at diagnosis. The mean OP was 29.1 (SD 6.2) mmHg. The mean BMI at diagnosis 37.1 (SD 
7.4) kg/m2. The mean CSF protein count at diagnosis was 277.2 (SD 140.1) mg/l. The most 
common symptoms at the time of diagnosis were headache (n=40, 78.4%) and visual 
disturbances (n= 38, 74.5%). Visual loss was reported in (n= 13, 25.5%) of cases, diplopia in 
(n= 10, 19.6%) of cases, and the rest various visual symptoms such as blurred eyesight. At 
presentation, tinnitus was reported by 23 (45.1%) patients, and dizziness by seven patients, 
(13.7%). 
 
3.2. Neuro-ophthalmological and Neuroimaging Findings at diagnosis 
Papilledema was found in all patients at the time of diagnosis, and bilaterally papillaedema in 
n=37, 72.5% of cases. Visual field defects were found in n=18 35.3% of patients. The mean 
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turcica was present in 12 (23.5%), and partial empty sella in 12 (23.5%) of the cases. The 
flattening of the posterior globes was present in 11 (21.6%), and increased CSF around optic 
nerves was found in 18 (35.3%) of cases. Four (7.8%) patients had protrusion of optic nerve 
head, and four (7.8%) patients had increased tortuosity of optic nerve.  
 
3.3. Psychiatric comorbidities in patients with IIH  
A total of 23 (45.1%) patients with IIH had pre-existing psychiatric diagnosis (Table 1). The 
most common psychiatric diagnosis was major depressive disorder (MDD), which was found 
in 19 (37.3%) patients. Psychotic disorders, including schizophrenia, psychotic episodes and 
schizoaffective disorder, were found in three (5.9%) patients. Other psychiatric diagnoses 
found in this IIH cohort were: personality disorder, suicidal ideations, dissociation disorder, 
adjustment disorder with anxiety, mixed obsessional thoughts and acts, panic disorder, 
bipolar disorder and substance abuse (Table 1). Multiple psychiatric diagnoses were found in 
eight (34.8%) patients. The most frequently used psychopharmaceutical drugs, based on 
clinical indications, were as follows: 1) antidepressant: escitalopram (n=7, 30.4 %), 2) 
antipsychotics: quetiapine (n=6, 26.1 %), 3) anti-anxiety medication: oxazepam (n=5, 21.7 
%), 4) hypnotics: melatonin (n=4, 17.4 %). 
 
3.4. Patients with IIH and psychiatric disorders at diagnosis 
The IIH patients with a prior psychiatric diagnosis did not differ in age gender distribution, 
BMI, or OP at diagnosis from patients with IIH who had no pre-existing psychiatric co-
morbidity. The CSF protein count was lower for patients with psychiatric disorder, though this 
difference was not significant. The presenting symptoms and neuro-ophthalmological 
findings were similarly distributed in both groups. The patients with IIH and pre-existing 
psychiatric diagnosis had more often empty sella in their initial MRI when compared to the 
patients with IIH without psychiatric co-morbidity (34.8% vs. 14.3%, p=0.044) (Table 2). 
 
3.5. Treatment types and outcomes after treatment 
Acetazolamide medication was used in almost all patients (97.9%), with a mean dosage at 
the beginning of treatment being 885.87 (SD 292.1) mg/day. The acetazolamide treatment 
was reported beneficial, i.e. complete resolution of all symptoms was observed in 20 (39.2%) 
of all patients, partial recovery was noted in 19 (37.3%) patients at the end of follow-up. The 
patients with no psychiatric disorders had better clinical outcome after acetazolamide 
treatment as compared to patients with IIH and pre-existing psychiatric diagnosis, (57.1% vs. 
17.4%, p=0.042) (Table 2). Surgical intervention was required for 16 (31.4%) patients, CSF 
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and three (23.1%) were ventriculoperitoneal. Gastric by-pass surgery was done in three (6%) 
patients. After conservative and operative treatments, the overt outcome improved slightly, 
as 26 (50.9%) patients reported themselves to be symptomless. In the group of patients with 
pre-existing psychiatric disorder, the outcomes were significantly worse as compared to 
patients without such history (26.1% vs. 71.4%, p=0.002) (Table 2). These patients 
continued having symptoms, such as headaches, dizziness, visual disturbances and fatigue. 
However, when neuro-ophthalmological outcome was assessed as a degree of resolution of 
papilledema, the outcome was equally good for both groups, and up to 71% of all patients 




In the present study, we analysed the prevalence and the type of psychiatric disorders in the 
patients with IIH. We found that 45% of the patients with IIH displayed pre-existing 
psychiatric co-morbidities. The most common psychiatric co-morbidity was major depressive 
disorder (MDD), found in over 37% of the cases. Patients with IIH and pre-existing 
psychiatric disorder did not differ from IIH-patients with no prior psychiatric diagnoses in 
terms of age, sex distribution, BMI or CSF opening pressure at diagnosis. Furthermore, their 
symptoms at presentation and the neuro-ophthalmological findings were similar in both 
groups. In the patients with psychiatric co-morbidities the only difference observed at the 
time of IIH diagnosis was higher prevalence of empty sella on the initial MRI scan. The empty 
sella may reflect propensity for pituitary gland related neuroendocrinological dysfunction and 
contribute to the development of comorbidities of IIH, including psychiatric conditions such as 
the affective disorders. However, metabolomic laboratory assays were not included to this 
study so the extent of hormonal dysfunction could not be assessed. 
 
The development of IIH has been suggested to be accompanied with HPA-axis dysfunction 
16, 27 which has been also implicated in the pathophysiology of a variety of mood and 
cognitive disorders. For example, neuroendocrine studies have consistently demonstrated 
HPA axis dysfunction in major depression (32). Another proposed mechanism that could 
explain why patients with IIH more frequently suffer from anxiety could be related to elevated 
catecholamine secretion observed in IIH (33). Nevertheless, the pathophysiology of IIH is still 
unclear and no single theory explains how raised ICP causes the condition. Due to the young 
and female preponderance, neuroendocrinological dysfunction might have a pivotal role in 
IIH 1,9,15,16. In addition, as obesity is highly prevalent in patients with IIH, it has been 
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development of IIH1. In particular, the dysfunction of the CSF hydrodynamics and aquaporins 
have been investigated as key components in understanding the aetiology of IIH 1,3,17,18. 
 
The patients with IIH and pre-existing psychiatric disorder were treated similarly as compared 
to the patients without prior psychiatric diagnoses. When only neuro-ophthalmological 
outcome was assessed as resolution of papilledema at the end of follow-up, there was no 
difference in outcome between these groups. However, after the conservative treatment, or 
both conservative and surgical interventions combined, patients with IIH and pre-existing 
psychiatric diagnosis had significantly poorer overall outcome. This outcome was a 
combination of neuro-ophthalmological signs and subjectively reported symptoms, such as 
headaches, fatigue, visual disturbances. These findings suggest, that the patients with IIH 
and pre-existing psychiatric disorder suffer from residual symptoms more often although their 
papilledema has improved, and they have been treated appropriately. 
 
Our results suggest that there is a high risk of MDD co-morbidity in patients with IIH, as 
recent reviews of epidemiological literature of MDD have established a global point-
prevalence (current or past month) of 4.7% and a pooled period prevalence of mood disorder 
(point of 12-month) of 5.4%30,31, as compared to our cohort the prevalence was sevenfold, 
37%.  There is little information as to the psychosocial impact of IIH, but there are some 
hypotheses on how psychiatric disorders might develop in individuals with IIH.  The 
development of IIH has been suggested to be accompanied with HPA-axis dysfunction16,27 
which has been also implicated in the pathophysiology of a variety of mood and cognitive 
disorders. For example, neuroendocrine studies have consistently demonstrated HPA axis 
dysfunction in major depression32. Another proposed mechanism that could explain why 
patients with IIH more frequently suffer from anxiety could be related to elevated 
catecholamine secretion observed in IIH33.  MDD was common in patients with IIH and in our 
study the patients had received their MDD diagnoses prior to the IIH diagnosis. Depressive 
symptoms may represent prodromal symptoms of IIH rather than a consequence of elevated 
ICP, but our register-based data did not allow drawing pathophysiology-based conclusions 
on the causal relationships between the two conditions. 
 
Kleinschmidt et al20 analysed how IIH affects symptoms of depression and anxiety and 
quality of life in a weight- and age-matched cross-sectional study and showed the patients 
with IIH suffered from higher levels of depression and anxiety as compared to the control 
groups. These findings were reflected in poorer quality of life in patients with IIH, and 
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treatment has also led to alleviation of IIH findings and subjective symptoms. Two case 
reports described electroconvulsive therapy improved both drug-refractory depression and 
IIH symptoms35,36 and one case reported antidepressants together with IIH treatment 
improved not only the IIH symptoms but also depression37. There are also cases when 
resolution of major depression has triggered IIH28,38.  
 
Our study is limited by factors inherent to a secondary analysis of retrospectively collected 
data as well as the small sample size. Nevertheless, there is a limited amount of previous 
data on this issue. This study represents a detailed investigation based on a well-defined 
cohort, which ensures a clinically comprehensive analysis and follow-up time for these 
patients, which we regard as a strength of this study. Nevertheless, further studies, focusing 
on the role of mental health adversities and the quality of life in patients with IIH in larger 
patient cohorts are needed. In 2017, we initiated a prospective collaborative multicentre 
study on IIH (www.iih.fi). In this study, we prospectively administer validated questionnaires, 
including Beck Depression Inventory, Beck’s Anxiety Inventory, Perceived Stress Scale, 
Headache Impact test-6 and Quality of Life (15D) questionnaires to screen and follow-up on 
mental well-being of patients with IIH, quality of life, and impact of their possible residual 
symptoms. Our aim is to increase the knowledge on pathophysiological mechanisms of IIH 
disease and to improve the diagnostics and management of IIH. We want to ameliorate the 
assessment of effectiveness of different treatment modalities, their follow-up protocol, and 
overall treatment outcomes. Finally, we also want to explore possible novel metabolic 
pathways as diagnostic or prognostic tools, and to unravel possible genomic variants of IIH. 
In this prospective study, in addition to gathering all clinical variables, we perform continuous 
lumbar ICP measurement, collect biological samples for further metabolomics and genetic 





Almost half of the patients with IIH suffered from psychiatric disorders, and these individuals 
continued to have residual symptoms although their ophthalmological outcomes improved. 
Psychiatric disorders appear to be common in IIH. They should be screened and treated 
promptly, as they may have an impact of treatment outcomes. IIH associates to 
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Fig 1. Flowchart of the study population: 65 patients with IIH from 2000 to 2018. Identification 




Fig. 2. Prospective IIH Research Protocol in Kuopio University Hospital. (Abbreviations: 15D = 
Quality of Life, BAI = Beck’s Anxiety Inventory, BDI = Beck’s Depression Inventory, cICP = continuous intracranial 
pressure, COHEN = Cohen’s Perceived Stress Scale, CRF = Clinical Research Form, CSF = Cerebrospinal fluid, 
ENT = Ear-Nose-Throat, GYN = Gynaecology, IIH = Idiopathic intracranial hypertension, KUH = Kuopio University 
Hospital, MRI = Magnetic Resonance Imaging, NEU = Neurology, PACS = Picture archiving and communication 


























Table 1. All psychiatric diagnoses of the IIH patients 
ICD-10 
Diagnosis 
Description n  (%) 
   
F10-F19 Mental and behavioral disorders due to psychoactive substance use 
F10.19 Substance abuse 1  (2) 
F20-F29 Schizophrenia, schizotypal, delusional, and other non-mood psychotic disorders 
F20 Paranoid schizophrenia 1  (2) 
F25.9 Schizoaffective disorder, unspecified 1  (2) 
F29 Unspecified psychosis not due to a substance or 
a known physiological condition 
1  (2) 
F30-39 Mood (affective) disorders 
F31.8 Bipolar II disorder 1  (2) 
F33 Major depressive disorders 19  (37.3) 
F40-F48 Anxiety, dissociative, stress-related, somatoform and other nonpsychotic mental 
disorders 
F41.0 Panic disorder 1  (2) 
F42.2 Mixed obsessional thoughts and acts 1  (2) 
F43.22 Adjustment disorder with anxiety 1  (2) 
F44.9 Dissociation disorder 1  (2) 
F60-F69 Disorders of adult personality and behavior 
F60.3 Personality disorders 2  (3.9) 
Symptoms and signs constituting part of a pattern of mental disorder 
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Table 2. Adult IIH patients with psychiatric disorders compared to IIH patients without psychiatric 
disorders 
 Patients without 
psychiatric disorder 
Patients with psychiatric 
disorder 
 
 n % n % p-value 
TOTAL 28 (54.9) 23 (45.1)  
Females 24 (85.7) 21 (91.3) 0.538 
Mean age in years (SD) 33.6 (12.6) 31.0 (7.9) 0.400 
Mean BMI kg/m2 (SD)  39.6 (7.2) 34.7 (7.0) 0.067 
Mean OP mmHg (SD)  28.4 (5.3) 29.4 (7.4) 0.768 
Mean CSF protein count mg/l 
(SD) 
308.52 (169.8) 242.6 (89.9) 0.139 
Neuroradiological findings at diagnosis 




   
11 (39.3) 10 (43.5) 0.044* 
10  (35.7) 2 (8.7)  
4 (14.3) 8 (34.8)  
Flattened sclera 6 (21.4) 5 (21.7) 0.922 
Increased CSF around CN II 8 (28.6) 10 (43.5) 0.203 
Intraocular protrusion of CN II 
head 
2 (7.1) 2 (8.7) 0.806 
Increased tortuosity of CN II 3 (10.7) 1 (4.3) 0.417 
Presenting symptoms 
Headache 21 (75.0) 19 (82.6) 0.601 
All visual symptoms 19 (67.9) 19 (82.6) 0.313 
Tinnitus 12 (42.9) 11 (47.8) 0.615 
Dizziness 3 (10.7) 4 (17.4) 0.536 
Neuro-opthalmological findings at diagnosis 
Optic nerve edema      
Slight  2 (7.1) 5 (21.7) 0.366 
Unilateral 4 (14.3) 2 (8.7)  
Bilateral 19 (67.9) 15 (65.2)  
Visual field defects  8 (28.6) 10 (43.5) 0.412 
Mean visual acuity (SD)      
Right eye 1.05 (0.31) 1.04 (0.33) 0.874 
Left eye  1.03 (0.36) 1.01 (0.35) 0.841 
Neuro-ophthalmological outcome after all treatments 
No papilledema 20 (71.4) 16 (69.6) 0.394 
Partial resolution of papilledema 6 (21.4) 7 (30.4)  
Papillar atrophy 2 (7.1) 0 (0)  
Effect of acetazolamide on papillae and symptoms 
Complete resolution of 
symptoms 
16 (57.1) 4 (17.4) 0.042* 
Slight improvement 7  (25.0) 12 (52.2)  
No improvement 5 (17.9) 5 (21.7)  
Effect of conservative and surgical treatments combined on papillae and symptoms 
Complete resolution of 
symptoms 
20  (71.4) 6 (26.1) 0.002* 
Slight improvement 8 (28.6) 16  (69.6)  
Abbreviations: BMI = Body mass index, CN = Cranial nerve, CSF = Cerebrospinal fluid, IIH = Idiopathic 
intracranial hypertension, OP = Opening pressure, SD = Standard deviation. p values were calculated by 
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